

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-101286-PIP01-23

Scope of the Application

Active Substance(s)

Varicella virus Oka strain (live, attenuated)

Condition(s)

Prevention of varicella

Pharmaceutical Form(s)

Powder and solvent for solution for injection

Route(s) of Administration

PARENTERAL USE

Name / Corporate name of the PIP applicant

GlaxoSmithKline UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, GlaxoSmithKline UK Limited submitted to the licensing authority on 06/12/2023 20:07 GMT an application for a

The procedure started on 12/02/2024 07:53 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Final Decision Letter

MHRA-101286-PIP01-23

Of 22/03/2024 17:02 GMT

On the adopted decision for Varicella virus Oka strain (live, attenuated) (MHRA-101286-PIP01-23) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a for Varicella virus Oka strain (live, attenuated), Powder and solvent for solution for injection , PARENTERAL USE .

This decision is addressed to GlaxoSmithKline UK Limited, 980 Great West Road, Brentford, UNITED KINGDOM, TW8 9GS

ANNEX I

1. Waiver

1.1 Condition:

Prevention of varicella The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Powder and solvent for solution for injection Route(s) of administration: PARENTERAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not Applicable

2.2 Indication(s) targeted by the PIP:

Not Applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not Applicable

2.4 Pharmaceutical Form(s):

Not Applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	